Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Carboplatin 195pembrolizumab 158Pemetrexed 136Cisplatin 119durvalumab 73Paclitaxel 72osimertinib 68Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 58Magnetic Resonance Spectroscopy 50Etoposide 47Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 21Platinum 20Radiation 19amivantamab 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biological Assay × Thoracic × 90 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡